I’m the Sam’s Club CEO and I’ve got an AI leadership reality check: let purpose, not promise, guide investment

At Sam’s Club, our technology decisions are grounded in a key part of the Walmart enterprise purpose: We are people-led and ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the US for adult patients with HER2-positive early breast cancer ...